Champions Oncology, Inc. (CSBR)
Automate Your Wheel Strategy on CSBR
With Tiblio's Option Bot, you can configure your own wheel strategy including CSBR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CSBR
- Rev/Share 3.242
- Book/Share 0.2743
- PB 27.0186
- Debt/Equity 1.6185
- CurrentRatio 0.9378
- ROIC 0.4645
- MktCap 102089052.0
- FreeCF/Share -0.0962
- PFCF -77.1648
- PE 21.6746
- Debt/Assets 0.1888
- DivYield 0
- ROE 1.9612
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CSBR | Craig Hallum | Hold | Buy | -- | $6 | Sept. 12, 2024 |
News
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
Published: July 21, 2025 by: Accesswire
Sentiment: Neutral
HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter and year ended April 30, 2025, on Wednesday, July 23, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Read More
Champions Oncology: Biological IP Is The Real Asset - Not Preclinical Services
Published: June 16, 2025 by: Seeking Alpha
Sentiment: Positive
Champions Oncology is transitioning from a traditional CRO to also a high-margin data licensing platform, unlocking new revenue and margin potential. The market undervalues CSBR, not reflecting its evolving business model and scalable, defensible oncology data assets in its current valuation. CSBR's unique, clinically-annotated PDX dataset and early AI/data licensing deals offer significant future upside as the business scales.
Read More
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance of seventeen abstracts for presentation at the AACR Annual Meeting, in Chicago, IL (April 25-30, 2025). These presentations will highlight Champions' cutting-edge research, featuring innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing, as well as AI-driven models that utilize multi-omics datasets to predict patient outcomes.
Read More
About Champions Oncology, Inc. (CSBR)
- IPO Date 2007-02-02
- Website https://www.championsoncology.com
- Industry Biotechnology
- CEO Ronnie Morris
- Employees 210